Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets.
The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, FDA-aligned protocol development, US-based scientific expertise, and international partnering opportunities.
Japan is one of the world’s largest and most advanced pharmaceutical markets, supported by a sophisticated research base and a rapidly evolving biotech sector. As more Japanese biopharma companies look to expand beyond domestic development and bring novel therapies to global markets, Novotech’s expanded presence in Tokyo strengthens its ability to support cross-border clinical trials and connect sponsors across Asia-Pacific, the United States, and Europe.
Novotech’s global operating model is particularly well aligned to the needs of emerging and growth-stage biopharma companies, providing flexible, high-quality clinical development support without the complexity of managing multiple regional providers. The company brings deep experience across therapeutic areas including oncology, rare diseases, central nervous system disorders, infectious diseases, immunology, and advanced therapies, supported by strong regulatory, scientific, and operational expertise across major clinical trial markets.
Takeshi Mori, Country Head, Japan, commented:
“The opening of our Tokyo office is an important milestone for Novotech. Japan is a critical market for global clinical development, and this investment reflects our long-term commitment to building strong local capabilities while delivering high-quality services to our clients.”
The office is located at:
27F Shinjuku i-Land Tower, 6-5-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan 163-1327
The opening of the Tokyo office builds on Novotech’s established presence in Japan and reflects its broader strategy to strengthen its global footprint and position itself as a leading CRO partner for biotech companies worldwide.
For similar news on , please read:
